Next Post

$500m CartiHeal sale to go ahead after FDA approval granted

&#13 US orthologics enterprise Bioventus (Nasdaq: BVS) can now commence with its $500 million acquisition of CartiHeal, following the Israeli clinical device firm received Food and drug administration clearance for its implants for the cure of damaged cartilage. Bioventus signed an agreement to purchase CartiHeal final July, for $350 million, […]